Q2 2026 Results Extend Cash Runway to October 2027 as FDA Clears Lucid-MS Phase 2
QNTM sits 68% above its 52-week low of $2.07.
Summary
Quantum BioPharma reported Q2 2026 financials with reduced cash burn and a cash runway to at least October 2027, while reiterating FDA clearance for its Lucid-MS Phase 2 trial.
Key Events · Earnings and Guidance · QNTM
-
Q2 2026 Financial Results
Operating expenses fell 53% YoY to US$2.29M; cash used in operations dropped 44% to US$3.46M for H1 2026.
-
Liquidity and Runway
Combined cash, cash equivalents, and digital assets totaled US$9.5M as of June 30, 2026, up from US$4.1M at year-end 2025; management confirms runway to at least October 2027.
-
Balance Sheet Strengthening
Total shareholders' equity rose 19% to US$6.09M; working capital improved to US$1.66M; current ratio increased to 1.2.
-
FDA Clearance for Lucid-MS Phase 2
Reiterates August 10, 2026 FDA approval to proceed with a randomized, double-blind, placebo-controlled Phase 2 trial in progressive MS.
Analysis · QNTM · Life Sciences
A 53% reduction in operating expenses and a strengthened balance sheet with US$9.5M in cash and digital assets extend Quantum BioPharma's runway to at least October 2027. The FDA clearance for Lucid-MS Phase 2, announced earlier this month, is reiterated alongside these financials, reinforcing the company's pivot toward clinical development. Improved liquidity and cost discipline reduce near-term financing risk, while the Phase 2 trial represents a key value inflection point for the lead asset.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.1% of the 1612 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNTM was trading at $3.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7M. The 52-week trading range was $2.07 to $25.30. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.